![]() ![]() The authors conclude that because of the limited duration of the cognitive improvement and the risks involved, 10 weeks of IV ceftriaxone was not an effective strategy for cognitive improvement in these patients, and more durable and safer treatment strategies are still needed. ![]() In addition, adverse effects attributed to IV ceftriaxone occurred in 26 percent of patients. In a complicated statistical model, the ceftriaxone group showed a slightly greater improvement at 12 weeks, but at 24 weeks both the ceftriaxone and the placebo groups had improved similarly from baseline. The patients were treated for Lyme disease and presented with objective memory impairment tests. Researchers compared clinical improvement following 10 weeks of IV ceftriaxone versus IV placebo. Overall, the study authors concluded that additional antibiotic therapy for PTLDS was not supported by the evidence.Īnother study supported by the National Institute of Neurological Disorders and Stroke again showed that long-term antibiotic use for Lyme disease is not an effective strategy for cognitive improvement. In addition, six of the study participants had serious adverse events associated with IV antibiotic use, four requiring hospitalization. However, no benefit to cognitive function was observed. In that study, people receiving antibiotics did report a greater improvement in fatigue than those on placebo. Patients were assessed for improvements in self-reported fatigue and cognitive function. In another study, published in 2003, researchers examined the effect of 28 days of IV antibiotic compared with placebo in 55 patients reporting persistent, severe fatigue at least six months following treatment for laboratory-diagnosed Lyme disease. However, results showed no benefit from prolonged antibiotic therapy when compared with placebo in treating those symptoms. These studies reinforced the evidence that patients reporting PTLDS symptoms have a severe impairment in overall physical health and quality of life. ![]() Patients were treated with 30 days of an intravenous (IV) antibiotic followed by 60 days of an oral antibiotic. Those symptoms are common among people reporting PTLDS. In those studies, physicians examined long-term antibiotic therapy in patients with a well-documented history of previous Lyme disease but who reported persistent pain, fatigue, impaired cognitive function, or unexplained numbness. The first clinical trial, which included two multicenter studies, provided no evidence that extended antibiotic treatment is beneficial.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |